AngioDynamics Reports Fiscal Year 2023 Fourth Quarter and Full-Year Financial Results; Issues Fiscal Year 2024 Guidance
Fiscal Year 2023 Fourth Quarter Highlights Net sales of $91.1 million increased 4.7% compared to the prior-year quarter Med Tech net sales of $26.5 million increased 17.2% Med Device net sales of $64.6 million increased 0.3% Gross margin of 50.9% declined 250 basis points year over year GAAP loss per share of $0.54, inclusive of a goodwill impairment of $14.5 million, or $0.37 per share, in connection with the transaction announced on June 8, 2023 Adjusted earnings per share of $0.02 Cash and cash equivalents at May 31, 2023 were $44.6 million On June 8, 2023, the Company completed the sale of...
Source: marketscreener.com
